What is Predictive Oncology Profitability Rank?
Predictive Oncology has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Predictive Oncology's Operating Margin % for the quarter that ended in Dec. 2023 was -1,046.57%. As of today, Predictive Oncology's Piotroski F-Score is 3.
Competitive Comparison of Predictive Oncology's Profitability Rank
For the Medical Instruments & Supplies subindustry, Predictive Oncology's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predictive Oncology's Profitability Rank Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Predictive Oncology's Profitability Rank falls into.
Predictive Oncology Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Predictive Oncology has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Predictive Oncology's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Predictive Oncology has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
Predictive Oncology Inc operating margin has been in a 5-year decline. The average rate of decline per year is -5.2%.
4. Consistency of the profitability
5. Predictability Rank
Predictive Oncology (Predictive Oncology) Business Description
Traded in Other Exchanges
N/A
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Executives
| Robert L Myers |
officer: CHIEF FINANCIAL OFFICER |
4765 BEACON HILL ROAD, EAGAN MN 55122 |
| Nuzum Charles Lee Sr |
director |
633 1ST STREET WEST, SONOMA CA 95476 |
| Veena Rao |
director |
2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
| Matthew Hawryluk |
director |
C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
| St. Clair Gregory Sr |
director |
1645 WHITLEY DRIVE, HARRISBURG PA 17111 |
| Nancy Chung-welch |
director |
P O BOX 1572, PEPPERELL MA 01463 |
| Pamela Bush |
officer: Chief Business Officer |
2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
| Daniel E Handley |
director |
1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765 |
| Raymond F Vennare |
director |
2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
| David Stewart Smith |
director |
151 WASHINGTON STREET, PITTSBURGH PA 15218 |
| J Melville Engle |
director |
1 REMINGTON COURT, NAPA CA 94558 |
| Jenkins Christina Lee Md |
director |
2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
| Carl I. Schwartz |
10 percent owner |
20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180 |
| Richard L Gabriel |
director |
900 COCOANUT AVENUE, SARASOTA FL 34236 |
| Pamela S Prior |
director |
2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
POAI has been successfully added to your